IDH2 mutant R/R AML responds to enasidenib monotherapy inducing a CR in ∼20% of patients. Measurable residual disease (MRD) monitoring will be helpful in predicting treatment response because response may occur as late as after the sixth cycle. Using enasidenib in first-line therapy or in combination with other therapies might further improve outcome and avoid resistance. These strategies will be further evaluated in ongoing studies, including maintenance therapy. Dx, diagnosis; “3+7,” standard chemotherapy with anthracycline and cytarabine. Bone marrow morphology images adapted from Stein et al.⁵